EP300 and osteosarcoma: The LbdCpf1-p300 construct was successfully employed to concurrently stimulate the expression of MYOD, a transcription factor linked to myogenic differentiation, and IL1RN, an interleukin-1 receptor antagonist, in U2OS (human osteosarcoma) and MCF7 cells [141].